Recently, immune checkpoint inhibitors were approved as a standard of care for first-line therapy in stage IV NSCLC, including anti-PD1 (nivolumab, pembrolizumab, and cemiplimab), anti-PD-L1 (atezolizumab and durvalumab), and anti-CTLA4 (ipilimumab) (85). This evidence concerns the gene CD274 and non-small cell lung carcinoma.